A phase III study (NCT02965716) aims to assess the effectiveness of talimogene laherparepvec (T-VEC) in combination with pembrolizumab (MK-3475) in treating patients who have progressed on prior anti-PD-1 or anti-PD-L1 therapy, either alone or in combination with other drugs other than talimogene laherparepvec (T-VEC) [213].c)Cancer Vaccines: Therapeutic vaccines like the MAGE-A3 vaccine target specific antigens expressed by cancer cells. Here, PDCD1 is linked to cancer.